Detalles de la búsqueda
1.
Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics.
Front Immunol;
15: 1385875, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38660306
2.
Chemotherapy-induced small extracellular vesicles prime the pre-metastatic niche to accelerate neuroblastoma metastasis.
Genes Dis;
11(4): 101017, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38495925
3.
Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers.
Eur J Med Chem;
263: 115940, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37976707
4.
Global role of IGF2BP1 in controlling the expression of Wnt/ß-catenin-regulated genes in colorectal cancer cells.
Front Cell Dev Biol;
11: 1236356, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37829185
5.
Generation of Novel Immunocompetent Mouse Cell Lines to Model Experimental Metastasis of High-Risk Neuroblastoma.
Cancers (Basel);
15(19)2023 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37835389
6.
Amyloid-ß exposed astrocytes induce iron transport from endothelial cells at the blood-brain barrier by altering the ratio of apo- and holo-transferrin.
J Neurochem;
167(2): 248-261, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37667496
7.
IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.
Front Immunol;
14: 1224516, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37503349
8.
Apo- and holo-transferrin differentially interact with hephaestin and ferroportin in a novel mechanism of cellular iron release regulation.
J Biomed Sci;
30(1): 36, 2023 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37277838
9.
Amyloid-ß exposed astrocytes induce iron transport from endothelial cells at the blood-brain barrier by altering the ratio of apo- and holo-transferrin.
bioRxiv;
2023 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37292926
10.
IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis.
Oncogene;
42(19): 1558-1571, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36973517
11.
Exosomes are involved in iron transport from human blood-brain barrier endothelial cells and are modified by endothelial cell iron status.
J Biol Chem;
299(2): 102868, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36603765
12.
Inhibition of insulin-like growth factor 2 mRNA-binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics.
FASEB Bioadv;
4(12): 816-829, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36479210
13.
Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
J Immunother Cancer;
10(4)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35483745
14.
Enhanced immunoprecipitation techniques for the identification of RNA-binding protein partners: IGF2BP1 interactions in mammary epithelial cells.
J Biol Chem;
298(3): 101649, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35104504
15.
Thoracic Neuroblastoma: A Novel Surgical Model for the Study of Extra-adrenal Neuroblastoma.
In Vivo;
36(1): 49-56, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34972699
16.
Distinct noncoding RNAs and RNA binding proteins associated with high-risk pediatric and adult acute myeloid leukemias detected by regulatory network analysis.
Cancer Rep (Hoboken);
5(10): e1592, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34862757
17.
Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells.
RNA Biol;
19(1): 26-43, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34895045
18.
Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents.
Front Oncol;
11: 608816, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33796454
19.
Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation.
Data Brief;
35: 106858, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33665254
20.
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Leukemia;
35(5): 1267-1278, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33531656